Renibus Therapeutics is developing RBT-1, a first-in-class intravenous drug designed to reduce postoperative complications in patients undergoing elective cardiac and valve surgeries. The company also offers Veverimer, an oral hydrochloric acid binder targeting orphan diseases with unmet medical needs, aiming to improve patient outcomes and protect against organ damage associated with cardio, renal, and metabolic diseases.
Funding
$130.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients undergoing elective cardiac and valve surgeries face the risk of postoperative complications. Additionally, there is an unmet need for treatments addressing orphan diseases associated with cardio, renal, and metabolic conditions.
Solution
Renibus Therapeutics is developing RBT-1, an intravenous drug designed to reduce postoperative complications in patients undergoing elective cardiac and valve surgeries. RBT-1 is administered 24-48 hours before surgery and is currently in a Phase 3 pivotal trial. The company also offers Veverimer, an oral hydrochloric acid binder, targeting orphan diseases with unmet medical needs, aiming to improve patient outcomes and protect against organ damage associated with cardio, renal, and metabolic diseases.
Target Audience
The primary target audience includes patients undergoing elective cardiac and valve surgeries, as well as individuals suffering from orphan diseases related to cardio, renal, and metabolic conditions.
Features
- RBT-1 (stannic protoporfin / iron sucrose): A single-dose IV drug administered 24-48 hours before elective cardiac and/or valve surgery.
- Veverimer: An oral, non-absorbed hydrochloric acid binder.